Professor Alon Chen is the President of Weizmann Institute of Science, Rehovot, Israel and a Director at the Max Planck Institute of Psychiatry, Munich Germany. Prof. Chen also serves as the Head of the Max Planck Society – Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and Behavioral Neurogenetics. Prof. Chen’s research focuses on the Neurobiology of Stress, particularly the mechanisms by which the brain is regulating the response to stressful challenges and how this response is linked to psychiatric disorders.
His lab has made discoveries linking the action of specific stress-related genes with anxiety, depression, social behaviors and metabolism. Prof. Chen and his research team use both mouse genetic models and human patients to ultimately create the scientific groundwork for therapeutic interventions to treat stress-related emotional disorders such as anxiety, post-traumatic stress, anorexia nervosa, and depression.
Michel Ben Horovitz
Chief executive officer
Former CFO of RXZ Investimentos, an investment company focused on listed and private equities. Mr. Horovitz was also a founding partner of two Brazilian Hedge Funds; Skopos Administradora de Recursos and VIX Investimentos. Mr. Horovitz holds a B.S. in Metallurgical Engineering from Universidade de São Paulo.
Head of Science
Head of Delivery Platform Technology
Andrés is the CEO and co-founder of CUBIQ FOODS (2018-present), a leading Spanish foodtech company. He is also Managing partner of Lingea Management & Consulting firm, supporting companies in Business development and Oligonucleotide delivery program development.
Before, as CEO, Senior Vice President, Research Head & Founder, of nLife Therapeutics (2006-2018, he has been involved in the development of oligonucleotides as therapeutic agents, published papers in the field of oligonculeotides for CNS therapies and issued the foundational patents. He holds a B.D. in Biotechnology from the Rosario University in Argentina and a PDD-2004 from IESE Business School (Spain).
Head of Strategy
MD from Federal University of Rio Grande do Sul Post Doctoral Fellow at The University of Texas MD Anderson Cancer Center MBA in Finance and Health Care Management from the Wharton School, University of Pennsylvania Founding Partner, One Partners
Served as Vice President, Movement and Neuromuscular Disorders Clinical Development at Biogen Idec between 2014-2019. Prior to joining Biogen, Dr. Cedarbaum was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squibb, where he was responsible for late-stage programs in neurology and psychiatry.
He has also held senior clinical development positions at Cytokinetics, Elan and Regeneron.
Dr. Ilana Fogelman is a physician/entrepreneur with 25 years of experience in drug development and regulatory affairs. She currently functions as COO of LifeTech Research (LTR), a due diligence and technology development company, and as VP of Clinical and Regulatory Affairs for C2N Diagnostics, an Alzheimer’s treatment and diagnostic company which she co-founded.
She obtained her MD from the University of Sao Paulo, and her MPH from Harvard where she also completed two post-doctoral fellowships. Prior to co-founding LTR in 2003, she worked as a FDA medical reviewer for 6 years, and as a Wall Street biotech analyst for another 3 years.
Jose Roberto Ferraz
J.R. Ferraz has 32 years of international experience in the healthcare industry leading organizations in a variety of segments such as Surgery, Specialty Pharma, E-commerce and retail OTC. He has held senior executive positions at Livanova plc, Nestle Health and Johnson & Johnson and had board experiences in Brazil and Internationally.
Mr. Ferraz holds bachelor’s degree in Business Administration and post graduated in International Marketing and Finance, with both honors being from Fundação Getulio Vargas (FGV).
Board of Directors
Chairman of the Board
Roberto Ruhman is Brazilian, currently living in London, and has a professional career of more than 35 years of experience in financial markets, investment banking and asset management sectors, both as an executive and as an entrepreneur. He graduated from business school (Escola de Administração de Empresas de São Paulo – Fundação Getúlio Vargas).
His career began at Citibank N.A. Brasil, and he worked at Banco Safra S/A. In both institutions, he was a senior bank executive in two different stints.
Roberto started his entrepreneurial activity when he founded Indosuez Capital Emerging Markets. He later joined Banco Matrix S/A as a partner. Roberto next went on to found RXZ Investimentos Ltda., an investment company. Additionally, between 2013-17, Roberto was a member of J. Rothschild Capital Management Limited’s Board of Directors. Currently, he is a founding partner of Joatinga Advisory UK Ltd, along with being the Chairman of the Board of miCure Therapeutics Ltd (an Israeli biotech start-up).
Bernardo Parnes, founding partner of Investment One Partners, has more than 30 years of experience leading renowned Brazilian and Global financial institutions. He was CEO for Latin America at Deutsche Bank and Chief Country Officer for Brazil.
He structured Banco Bradesco BBI S/A, and managed JSI Investimentos Ltda., Joseph Safra’s family office. He was president of Merrill Lynch Brazil for more than 10 years, having started his career in finance at Citibank, where he worked for 7 years.
Marcelo Bandeira de Mello
Former partner and manager of Banco Matrix S.A., where he worked for eight years. Lawyer and partner of law firms for more than ten years, performing in corporate and tax areas, capital markets and estate planning.
Graduated from Pontifícia Universidade Católicade São Paulo (PUC/SP), in 1987, with a J.D.